Adjuvant immunotherapy for cervical cancer. Two randomized controlled studies using OK-432 or sizofiran

J Chemother. 1989 Jul;1(4 Suppl):1222-4.

Authors

K Okamura¹, A Yajima, K Noda

Affiliation

¹ Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1-1 Seiryo machi, Sendai 980, Japan.

PMID: 16312843

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease-Free Survival
Female
Humans
Immunotherapy / methods
Neoplasm Staging
Picibanil / administration & dosage
Randomized Controlled Trials as Topic
Sizofiran / administration & dosage
Survival Analysis
Uterine Cervical Neoplasms / drug therapy*
Uterine Cervical Neoplasms / mortality
Uterine Cervical Neoplasms / pathology

Substances

Picibanil
Sizofiran